Biphasic Expression of Atypical Chemokine Receptor (ACKR) 2 and ACKR4 in Colorectal Neoplasms in Association with Histopathological Findings
Open Access
- 23 December 2020
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (1) , 8
Abstract
Facilitating resolution of inflammation using atypical chemokine receptors (ACKR) as an anticancer strategy is considered but requires a deeper understanding of receptor role in carcinogenesis. We aimed at transcriptional analysis (RTqPCR) of ACKR2 and ACKR4 expression in colorectal adenoma-adenocarcinoma sequence in paired normal-neoplastic tissues from 96 polyps and 51 cancers. On average, ACKR2 was downregulated in neoplastic as compared to non-affected tissue in polyp (by 2.7-fold) and cancer (by 3.1-fold) patients. The maximal downregulation (by 8.2-fold) was observed in adenomas with the highest potential for malignancy and was gradually lessening through cancer stages I-IV, owing to increased receptor expression in tumors. On average, ACKR4 was significantly downregulated solely in adenocarcinomas (by 1.5-fold), less so in patients with lymph node metastasis, owing to a gradual decrease in ACKR4 expression among N0-N1-N2 cancers in non-affected tissue without changes in tumors. In adenomas, ACKR4 downregulation in neoplastic tissue increased with increasing potential for malignancy and contribution of villous growth pattern. ACKR4 expression increased in non-affected tissue with a concomitant decrease in pathological mucosa. In conclusion, the changes in ACKRs expression occur already in precancerous colorectal lesions, culminating in the adenomas with the highest potential for malignancy. Therefore, chemoprevention by manipulating ACKRs’ expression is worth exploration.Keywords
Funding Information
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu (SUB.A040.19.016)
This publication has 47 references indexed in Scilit:
- How Many Diseases Are Colorectal Cancer?Gastroenterology Research and Practice, 2012
- Tumor location determines midkine level and its association with the disease progression in colorectal cancer patients: a pilot studyInternational Journal of Colorectal Disease, 2012
- Colorectal cancer: a tale of two sides or a continuum?: Figure 1Gut, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The Inflammatory Microenvironment in Colorectal NeoplasiaPLOS ONE, 2011
- Inflammation and colorectal cancerCurrent Opinion in Pharmacology, 2009
- Involvement of a Novel Chemokine Decoy Receptor CCX-CKR in Breast Cancer Growth, Metastasis and Patient SurvivalClinical Cancer Research, 2009
- Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapyBritish Journal of Cancer, 2009
- Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind TrialCancer Prevention Research, 2008
- Clinical implications and utility of field cancerizationCancer Cell International, 2007